System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Johan Maertens is an expert in Hematology at Universitair Ziekenhuis Leuven (Belgium). As of October 2026, ScienceLeadR ranks Johan Maertens in the top 1% of experts worldwide for Mycoses, Neutropenia and Cell Transplantation. Johan Maertens has authored 831 publications, the most recent in 2026, and is an investigator in 61 clinical trials, 7 of them ongoing. SLR score: 3,019 (community average: 125). How the SLR is computed.

LeadR Profile

Johan Maertens Universitair Ziekenhuis Leuven Belgium
3 019 ScienceLeadR Reputation 3019

Unlock

Register Login
Network Map

Hematology

Subspecialties: Infectiology - Transplantation - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1998 - 2026
Source: PubMed

Universitair Ziekenhuis Leuven

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 831

Citations

Citations: 51 819 1st author: 75 Last author: 52 Unique author: 8

Main journals

Blood 156
Bone Marrow Transplant 78
J Antimicrob Chemother 41
Clin Infect Dis 37
Haematologica 32

Best Journals

N Engl J Med 9
Intensive Care Med 4
J Clin Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
The immunophenotypic landscape of newly diagnosed acute myeloid leukemia: Associations with genotype and outcomes.
PMID 42903857 — cells, flow cytometry, genomics, bone marrow, immunophenotyping, leukemia, leukemia, myeloid, acute, machine learning, leukemia, myeloid, genotype, mutation		iScience20260
Non-invasive diagnosis of invasive aspergillosis in patients with haematological malignancies: a prospective diagnostic accuracy study.
PMID 42858895 — serum, microbiology, parasitic diseases, diagnosis, communicable diseases, aspergillosis, infections, pentraxins		Clin Microbiol Infect20260
Choice of a different donor reduces relapse risk after second allogeneic SCT for MDS.
PMID 42842316		Blood20260
Performance of the Urinary MycoMEIA Aspergillus Assay as an Aid to Diagnose Invasive Aspergillosis.
PMID 42841776 — research design, serum, aspergillus, diagnosis, communicable diseases, aspergillosis		Clin Infect Dis20260
Treatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients.
PMID 42774582 — registries, mortality, candidiasis, adrenal cortex hormones, duration of therapy, amphotericin b, therapeutics		EClinicalMedicine20260

Clinical Studies 61

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 10

By phase:

Phase 3 29
Phase 2 12
N/A 8
Phase 1 5
Phase 4 4
Phase 1/Phase 2 2
Phase 2/Phase 3 1

By status:

Completed 35
Recruiting 13
Terminated 7
Active not recruiting 2
Not yet recruiting 2
Unknown 2

By type:

Interventional 57
Observational 4

By Monocentric/Multicentric:

monocentric 14
multicentric2to4 2
multicentric5to9 6
multicentricup10 39

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 1 2 study of Enzomenib (DSP 5336) in Patients with Acute leukemia
2022-502741-10-00 — hematologic neoplasms, leukemia, mutation		Phase 1/Phase 2Recruiting2024
A study to investigate the effect of adding bleximenib to standard of care treatment with intensive chemotherapy in patients with a specific type of acute myeloid leukemia (AML)
2025-522767-15-00 — leukemia, drug therapy, leukemia, myeloid, acute, maintenance, leukemia, myeloid, therapeutics, chemotherapy		Phase 3Not yet recruiting2026
Phase 2 EL219 versus Liposomal Amphotericin B for Early Antifungal Therapy
2025-522835-32-00 — voriconazole, safety, double-blind method, amphotericin b, therapeutics, infections		Phase 2Recruiting2026
A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult patients with invasive mold infections
2024-516216-16-00 — safety, cohort studies, aspergillus, fungi, mucorales, therapeutics, infections, fusarium		Phase 3Recruiting2026
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy
2024-512753-24-00 — genes, leukemia, drug therapy, leukemia, myeloid, acute, azacitidine, leukemia, myeloid, therapeutics, chemotherapy		Phase 3Not yet recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS